Supernus Pharmaceuticals Inc (SUPN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Supernus Pharmaceuticals Inc (SUPN) has a cash flow conversion efficiency ratio of -0.005x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.81 Million) by net assets ($1.03 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SUPN company net worth for the company's overall valuation and market capitalisation.
Supernus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Supernus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Supernus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Supernus Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Supernus Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Central Puerto S.A.
BA:CEPU
|
0.014x |
|
CNNC Hua Yuan Titanium Dioxide Co Ltd
SHE:002145
|
0.002x |
|
Newell Brands Inc
NASDAQ:NWL
|
0.012x |
|
Bavarian Nordic
CO:BAVA
|
0.042x |
|
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ:NAMS
|
-0.045x |
|
Beam Therapeutics Inc
NASDAQ:BEAM
|
-0.062x |
|
Bure Equity AB
ST:BURE
|
0.016x |
|
Maple Leaf Foods Inc.
TO:MFI
|
0.044x |
Annual Cash Flow Conversion Efficiency for Supernus Pharmaceuticals Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Supernus Pharmaceuticals Inc from 2008 to 2025. View SUPN share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.06 Billion | $47.33 Million | 0.045x | -73.15% |
| 2024-12-31 | $1.04 Billion | $171.95 Million | 0.166x | +37.72% |
| 2023-12-31 | $921.52 Million | $111.08 Million | 0.121x | -8.56% |
| 2022-12-31 | $886.20 Million | $116.83 Million | 0.132x | -15.40% |
| 2021-12-31 | $815.85 Million | $127.13 Million | 0.156x | -16.14% |
| 2020-12-31 | $744.86 Million | $138.40 Million | 0.186x | -22.70% |
| 2019-12-31 | $595.43 Million | $143.13 Million | 0.240x | -15.57% |
| 2018-12-31 | $453.02 Million | $128.99 Million | 0.285x | -33.57% |
| 2017-12-31 | $267.48 Million | $114.64 Million | 0.429x | +23.01% |
| 2016-12-31 | $191.75 Million | $66.81 Million | 0.348x | +28.94% |
| 2015-12-31 | $118.88 Million | $32.12 Million | 0.270x | +149.34% |
| 2014-12-31 | $71.35 Million | $7.73 Million | 0.108x | +106.26% |
| 2013-12-31 | $33.46 Million | $-57.95 Million | -1.732x | -111.22% |
| 2012-12-31 | $57.57 Million | $-47.20 Million | -0.820x | +78.60% |
| 2011-12-31 | $9.44 Million | $-36.19 Million | -3.832x | -621.85% |
| 2010-12-31 | $-44.32 Million | $-32.54 Million | 0.734x | +271.61% |
| 2009-12-31 | $-6.16 Million | $2.63 Million | -0.428x | -109.74% |
| 2008-12-31 | $-6.75 Million | $-29.65 Million | 4.395x | -- |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with P… Read more